SG Americas Securities LLC lifted its holdings in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 3,174.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 172,525 shares of the biotechnology company’s stock after purchasing an additional 167,256 shares during the quarter. SG Americas Securities LLC owned 0.45% of Spark Therapeutics worth $16,731,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of ONCE. Havens Advisors LLC grew its holdings in shares of Spark Therapeutics by 114.8% during the second quarter. Havens Advisors LLC now owns 53,700 shares of the biotechnology company’s stock worth $5,498,000 after purchasing an additional 28,700 shares in the last quarter. Rhenman & Partners Asset Management AB purchased a new stake in Spark Therapeutics in the second quarter worth approximately $1,024,000. Strs Ohio purchased a new stake in Spark Therapeutics in the second quarter worth approximately $409,000. ARP Americas LP boosted its stake in Spark Therapeutics by 41.7% in the second quarter. ARP Americas LP now owns 228,617 shares of the biotechnology company’s stock worth $23,406,000 after buying an additional 67,286 shares in the last quarter. Finally, Janney Montgomery Scott LLC purchased a new stake in Spark Therapeutics in the second quarter worth approximately $202,000. 86.35% of the stock is owned by institutional investors.
ONCE traded up $0.03 during midday trading on Friday, hitting $111.58. The stock had a trading volume of 397,500 shares, compared to its average volume of 939,219. The company has a market cap of $4.30 billion, a P/E ratio of -52.88 and a beta of 2.08. The business has a fifty day moving average of $102.20 and a 200 day moving average of $102.99. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.22 and a current ratio of 5.56. Spark Therapeutics Inc has a 1 year low of $34.53 and a 1 year high of $114.20.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($0.58). Spark Therapeutics had a negative net margin of 397.68% and a negative return on equity of 48.70%. The company had revenue of $13.50 million during the quarter, compared to the consensus estimate of $27.71 million. On average, equities research analysts anticipate that Spark Therapeutics Inc will post -4.97 earnings per share for the current year.
Several analysts have issued reports on the company. Mizuho reaffirmed a “hold” rating and issued a $114.50 target price on shares of Spark Therapeutics in a research note on Monday, August 12th. Zacks Investment Research lowered Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 14th. Finally, ValuEngine raised Spark Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $106.00.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Recommended Story: Hedge Funds – How They Work For Investors
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.